Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Proteomics Analysis of Trastuzumab Toxicity in the H9c2 Cardiomyoblast Cell Line and Its Inhibition by Carvedilol Publisher Pubmed



Beiranvand E1 ; Torkashvand F1 ; Ostad SN2 ; Mirzaie M3, 4 ; Ardakani EM1 ; Zandi F1 ; Sardari S1 ; Salekdeh GH5 ; Shokrgozar MA6 ; Vaziri B1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Protein Chemistry and Proteomics Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  2. 2. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Molecular Sciences, Macquarie University, Sydney, NSW, Australia
  4. 4. Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW, Australia
  5. 5. Department of Molecular Systems Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  6. 6. National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

Source: Current Pharmaceutical Biotechnology Published:2020


Abstract

Objective: Heart dysfunctions are the major complications of trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive breast cancers. Methods: In this study, the cytotoxicity of trastuzumab on H9c2 cardiomyoblasts was demonstrated, and the proteome changes of cells were investigated by a tandem mass tagging quantitative approach. The differentially abundant proteins (DAPs) were identified and functionally enriched. Results: We determined that carvedilol, a non-selective beta-blocker, could effectively inhibit trastuzumab toxicity when administrated in a proper dose and at the same time. The proteomics analysis of carvedilol co-treated cardiomyoblasts showed complete or partial reversion in expressional levels of trastuzumab-induced DAPs. Conclusion: Downregulation of proteins involved in the translation biological process is one of the most important changes induced by trastuzumab and reversed by carvedilol. These findings provide novel insights to develop new strategies for the cardiotoxicity of trastuzumab. © 2020, Bentham Science Publishers. All rights reserved.
Related Docs
1. In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity, Drug Research (2020)
2. Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced Her2-Positive Breast Cancer Patients, International Journal of Hematology-Oncology and Stem Cell Research (2021)
Experts (# of related papers)
View all Related Experts
Ayat Ahmadi Saraeilani (1)
Azadeh Sadat Naseri (1)